FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1154-1156 September 13, 2007 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Agosti, J. M. Related Article by Sawaya, G. F. Related Article by The FUTURE II Study Group Related Article by Garland, S. M. PubMed Citation

To the Editor: In their editorial about the availability of a quadrivalent vaccine against human papillomavirus (HPV) (Gardasil, Merck) that was reported on by Garland et al.¹ and by the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) II Study Group² (May 10 issue), Sawaya and Smith-McCune³ raise concerns regarding the adequacy of cervical dysplasia as an efficacy end point, disease due to HPV types not associated with the vaccine, the lower efficacy of the vaccine among women who were previously infected with HPV than among those who had never been infected, and the need for continued Papanicolaou screening after . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.